Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway

Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics

(2010) Scott E. Woodman et al.   BIOCHEMICAL PHARMACOLOGY

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells

(2009) Gregory B. Lesinski et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Understanding Melanoma Signaling Networks as the Basis for Molecular Targeted Therapy

(2009) Keiran S.M. Smalley   JOURNAL OF INVESTIGATIVE DERMATOLOGY

KIT as a Therapeutic Target in Melanoma

(2009) Maria C. Garrido et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Molecular Pathogenesis of Cutaneous Melanocytic Neoplasms

(2008) Nageatte Ibrahim et al.   Annual Review of Pathology-Mechanisms of Disease

Phase II trial of imatinib mesylate in patients with metastatic melanoma

(2008) K B Kim et al.   BRITISH JOURNAL OF CANCER

Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines

(2008) A. Sorolla et al.   BRITISH JOURNAL OF DERMATOLOGY

Synergistic anti‐proliferative and pro‐apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti‐epidermal growth factor receptor (EGFR) drugs in human cancer cells

(2008) Tina Cascone et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Melanoma Genetics and Therapeutic Approaches in the 21st Century: Moving from the Benchside to the Bedside

(2008) Thomas L. Hocker et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Absence of PDGFRA Mutations in Primary Melanoma

(2007) John A. Curtin et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY